FDA Grants Priority Review to GSK’s Gepotidacin for Uncomplicated Urinary Tract Infections

Priority Review status for GSK’s New Drug Application for gepotidacin was based on promising results from the Phase III EAGLE-2 and EAGLE-3 trials, which demonstrated non-inferiority to nitrofurantoin in uncomplicated urinary tract infections.